molecular therapy targeted for (pro) renin receptor against glioblastoma

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K20712
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0801:Pharmaceutical sciences and related fields
• Research Institution: Kagawa University
• Principal Investigator: Fujimori Takeshi 香川大学, 医学部附属病院, 助教 (00896417)
• Project Period (FY): 2022-08-31 – 2024-03-31
• Keywords: (pro)renin receptor / glioblastoma / gliomagenisis / Wnt signaling pathway

Outline of Final Research Achievements

The efficacy of PRR antibodies against GBM was investigated using human glioma cell lines and glioma stem cell lines, with each cell line showing efficacy in cell proliferation, sphere formation, apoptosis and migration. The efficacy was confirmed in each cell line in cell proliferation, sphere formation, apoptosis and migration. In vivo studies using U87MG also demonstrated tumour suppression. In addition, focusing on stemness, a correlation was found between stemness markers and PRR in pathological specimens, proving that PRR antibodies also have a suppressive effect on stemness. From these results, it was concluded that PRR antibodies could be used to treat GBM.

Free Research Field

脳血管障害

Academic Significance and Societal Importance of the Research Achievements

PRRはWnt/β-catenin signaling pathwayの関連分子として注目されており、多くの癌種においても腫瘍抑制効果が報告されている。一方、現在腫瘍研究においてstemnessは
key wordの一つである。PRRがより腫瘍増殖の根幹に関わるstemnessと関係することを示し、PRR抗体にstemnessの抑制効果があることを証明した。PPRに関わる研究の中でも、GBMにおけるstemnessとの関連は検討されておらず、学術的に意義のある結果となった。今後分子標的薬として実用化されれば、社会的もより意義のある研究であったと言える。